References:
1.
Keating
GM. Posaconazole. Drugs . 2005;65(11):1553-67; discussion 1568-9
2.
Torres
HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a
broad-spectrum triazole antifungal. Lancet Infect Dis .
2005;5(12):775-85
3.
Groll
AH, Walsh TJ. Posaconazole: clinical pharmacology and potential for
management of fungal infections. Expert Rev Anti Infect Ther .
2005;3(4):467-87
4.
Vicenzi
EB, Cesaro S. Posaconazole in immunocompromised pediatric patients.Expert Rev Anti Infect Ther . 2018;16(7):543-553
5.
Assasi
N, Grobelna A. Posaconazole for the Prophylaxis and Treatment of
Invasive Aspergillosis: A Review of Clinical Effectiveness and
Guidelines. 2017;
6.
Lyseng-Williamson
KA. Posaconazole: a pharmacoeconomic review of its use in the
prophylaxis of invasive fungal disease in immunocompromised hosts.Pharmacoeconomics . 2011;29(3):251-68
7.
Schiller
DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal
agent. Clin Ther . 2007;29(9):1862-86
8.
John
J, Loo A, Mazur S, Walsh TJ. Therapeutic drug monitoring of systemic
antifungal agents: a pragmatic approach for adult and pediatric
patients. Expert Opin Drug Metab Toxicol . 2019;15(11):881-895
9. Ji
W, Zhao H, Yang S, Wen Q, He K. Pharmacokinetics and tolerability of
intravenous posaconazole in healthy Chinese volunteers: a randomized,
open-label and single-dose study. Pharmazie . 2020;75(10):491-493
10.
Sime
FB, Stuart J, Butler J et al. Pharmacokinetics of Intravenous
Posaconazole in Critically Ill Patients. Antimicrob Agents
Chemother . 2018;62(6)
11.
Ray J,
Campbell L, Rudham S, Nguyen Q, Marriott D. Posaconazole plasma
concentrations in critically ill patients. Ther Drug Monit .
2011;33(4):387-92
12.
Mattiuzzi
G, Yilmaz M, Kantarjian H et al. Pharmacokinetics of posaconazole
prophylaxis of patients with acute myeloid leukemia. J Infect
Chemother . 2015;21(9):663-7
13.
Walravens
J, Brouwers J, Spriet I et al. Effect of pH and comedication on
gastrointestinal absorption of posaconazole: monitoring of intraluminal
and plasma drug concentrations. Clin Pharmacokinet .
2011;50(11):725-34
14.
Kersemaekers
WM, Dogterom P, Xu J et al. Effect of a high-fat meal on the
pharmacokinetics of 300-milligram posaconazole in a solid oral tablet
formulation. Antimicrob Agents Chemother . 2015;59(6):3385-9
15.
Krishna
G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption
of posaconazole oral suspension under various gastric conditions in
healthy volunteers. Antimicrob Agents Chemother .
2009;53(3):958-66
16.
van
der Elst KC, Brouwers CH, van den Heuvel ER et al. Subtherapeutic
Posaconazole Exposure and Treatment Outcome in Patients With Invasive
Fungal Disease. Ther Drug Monit . 2015;37(6):766-71
17.
Alffenaar
JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR. Omeprazole
significantly reduces posaconazole serum trough level. Clin Infect
Dis . 2009;48(6):839
18.
Dolton
MJ, Brüggemann RJ, Burger DM, McLachlan AJ. Understanding variability in
posaconazole exposure using an integrated population pharmacokinetic
analysis. Antimicrob Agents Chemother . 2014;58(11):6879-85
19.
Dekkers
B, Bakker M, van der Elst K et al. Therapeutic Drug Monitoring of
Posaconazole: an Update. Curr Fungal Infect Rep . 2016;10:51-61
20.
Walsh
TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with
posaconazole in patients who are refractory to or intolerant of
conventional therapy: an externally controlled trial. Clin Infect
Dis . 2007;44(1):2-12
21. Li
Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H.
Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin
Pharmacokinet . 2010;49(6):379-96
22.
Chen
L, Krekels E, Verweij PE et al. Pharmacokinetics and Pharmacodynamics of
Posaconazole. Drugs . 2020;80(7):671-695
23.
Kohl
V, Müller C, Cornely OA et al. Factors influencing pharmacokinetics of
prophylactic posaconazole in patients undergoing allogeneic stem cell
transplantation. Antimicrob Agents Chemother . 2010;54(1):207-12
24.
AbuTarif
MA, Krishna G, Statkevich P. Population pharmacokinetics of posaconazole
in neutropenic patients receiving chemotherapy for acute myelogenous
leukemia or myelodysplastic syndrome. Curr Med Res Opin .
2010;26(2):397-405
25.
Vehreschild
JJ, Müller C, Farowski F et al. Factors influencing the pharmacokinetics
of prophylactic posaconazole oral suspension in patients with acute
myeloid leukemia or myelodysplastic syndrome. Eur J Clin
Pharmacol . 2012;68(6):987-95
26.
Störzinger
D, Borghorst S, Hofer S et al. Plasma concentrations of posaconazole
administered via nasogastric tube in patients in a surgical intensive
care unit. Antimicrob Agents Chemother . 2012;56(8):4468-70
27.
Petitcollin
A, Boglione-Kerrien C, Tron C et al. Population Pharmacokinetics of
Posaconazole Tablets and Monte Carlo Simulations To Determine whether
All Patients Should Receive the Same Dose. Antimicrob Agents
Chemother . 2017;61(11)
28.
van
Iersel M, Rossenu S, de Greef R, Waskin H. A Population Pharmacokinetic
Model for a Solid Oral Tablet Formulation of Posaconazole.Antimicrob Agents Chemother . 2018;62(7)
29.
Boonsathorn
S, Cheng I, Kloprogge F et al. Clinical Pharmacokinetics and Dose
Recommendations for Posaconazole in Infants and Children. Clin
Pharmacokinet . 2019;58(1):53-61
30.
Wasmann
RE, Smit C, van Donselaar MH et al. Implications for IV posaconazole
dosing in the era of obesity. J Antimicrob Chemother .
2020;75(4):1006-1013
31.
Peña-Lorenzo
D, Rebollo N, Sánchez-Hernández JG et al. Population pharmacokinetics of
a posaconazole tablet formulation in transplant adult allogeneic stem
cell recipients. Eur J Pharm Sci . 2022;168:106049
32.
Bentley
S, Davies JC, Gastine S, Donovan J, Standing JF. Clinical
pharmacokinetics and dose recommendations for posaconazole
gastroresistant tablets in children with cystic fibrosis. J
Antimicrob Chemother . 2021;76(12):3247-3254
33.
Elkayal
O, Spriet I, Uyttebroeck A et al. A Population Pharmacokinetic Modeling
and Simulation Study of Posaconazole Oral Suspension in
Immunocompromised Pediatric Patients: A Short Communication. Ther
Drug Monit . 2021;43(4):512-518
34.
Van
Daele R, Brüggemann RJ, Dreesen E et al. Pharmacokinetics and target
attainment of intravenous posaconazole in critically ill patients during
extracorporeal membrane oxygenation. J Antimicrob Chemother .
2021;76(5):1234-1241
35.
Shi C,
Xiao Y, Mao Y, Wu J, Lin N. Voriconazole: A Review of Population
Pharmacokinetic Analyses. Clin Pharmacokinet . 2019;58(6):687-703
36.
Gwee
A, Cranswick N, Curtis N. Posaconazole: promising but problematic in
practice in pediatric patients. Pediatr Infect Dis J .
2015;34(6):604-6
37.
Clark
NM, Grim SA, Lynch JR. Posaconazole: Use in the Prophylaxis and
Treatment of Fungal Infections. Semin Respir Crit Care Med .
2015;36(5):767-85
38.
Morris
MI. Posaconazole: a new oral antifungal agent with an expanded spectrum
of activity. Am J Health Syst Pharm . 2009;66(3):225-36
39.
Cornely
OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or
itraconazole prophylaxis in patients with neutropenia. N Engl J
Med . 2007;356(4):348-59
40.
Döring
M, Blume O, Haufe S et al. Comparison of itraconazole, voriconazole, and
posaconazole as oral antifungal prophylaxis in pediatric patients
following allogeneic hematopoietic stem cell transplantation. Eur
J Clin Microbiol Infect Dis . 2014;33(4):629-38
41.
Döring
M, Eikemeier M, Cabanillas SK et al. Antifungal prophylaxis with
posaconazole vs. fluconazole or itraconazole in pediatric patients with
neutropenia. Eur J Clin Microbiol Infect Dis . 2015;34(6):1189-200
42.
Takpradit
C, Wangkittikal C, Rungmaitree S et al. Antifungal Prophylaxis with
Posaconazole versus Fluconazole in Children with Neutropenia Following
Allogeneic Hematopoietic Stem Cell Transplantation: Single Center
Experience. J Blood Med . 2021;12:679-689
43.
Jancel
T, Shaw PA, Hallahan CW et al. Therapeutic drug monitoring of
posaconazole oral suspension in paediatric patients younger than 13
years of age: a retrospective analysis and literature review. J
Clin Pharm Ther . 2017;42(1):75-79
44.
Döring
M, Cabanillas SK, Klinker H et al. Posaconazole plasma concentrations in
pediatric patients receiving antifungal prophylaxis during neutropenia.Med Mycol . 2017;55(4):375-384
45.
Krishna
G, AbuTarif M, Xuan F et al. Pharmacokinetics of oral posaconazole in
neutropenic patients receiving chemotherapy for acute myelogenous
leukemia or myelodysplastic syndrome. Pharmacotherapy .
2008;28(10):1223-32
46.
Krishna
G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of
oral posaconazole in allogeneic hematopoietic stem cell transplant
recipients with graft-versus-host disease. Pharmacotherapy .
2007;27(12):1627-36
47.
Tang
LA, Marini BL, Benitez L et al. Risk factors for subtherapeutic levels
of posaconazole tablet. J Antimicrob Chemother .
2017;72(10):2902-2905
48.
Gautier-Veyret
E, Bolcato L, Roustit M et al. Treatment by Posaconazole Tablets,
Compared to Posaconazole Suspension, Does Not Reduce Variability of
Posaconazole Trough Concentrations. Antimicrob Agents Chemother .
2019;63(10)
49.
Shields
RK, Clancy CJ, Vadnerkar A et al. Posaconazole serum concentrations
among cardiothoracic transplant recipients: factors impacting trough
levels and correlation with clinical response to therapy.Antimicrob Agents Chemother . 2011;55(3):1308-11
50.
Steinberg
KP. Stress-related mucosal disease in the critically ill patient: risk
factors and strategies to prevent stress-related bleeding in the
intensive care unit. Crit Care Med . 2002;30(6 Suppl):S362-4
51.
Monnig
AA, Prittie JE. A review of stress-related mucosal disease. J Vet
Emerg Crit Care (San Antonio) . 2011;21(5):484-95
52.
Wang
WH, Huang JQ, Zheng GF et al. Head-to-head comparison of H2-receptor
antagonists and proton pump inhibitors in the treatment of erosive
esophagitis: a meta-analysis. World J Gastroenterol .
2005;11(26):4067-77
53.
Panagopoulou
P, Roilides E. Evaluating posaconazole, its pharmacology, efficacy and
safety for the prophylaxis and treatment of fungal infections.Expert Opin Pharmacother . 2022;23(2):175-199
54.
Jia
MM, Zhang QW, Qin ZF et al. Deciphering the Relationship Between the
Trough Concentration of Posaconazole and Its Efficacy and Safety in
Chinese Patients With Hematological Disorders. Front Pharmacol .
2020;11:575463
55.
Cojutti
PG, Candoni A, Lazzarotto D et al. Co-administration of proton pump
inhibitors and/or of steroids may be a risk factor for low trough
concentrations of posaconazole delayed-released tablets in adult
patients with haematological malignancies. Br J Clin Pharmacol .
2018;84(11):2544-2550
56.
Allegra
S, Fatiguso G, De Francia S et al. Evaluation of Posaconazole
Pharmacokinetics in Adult Patients with Invasive Fungal Infection.Biomedicines . 2017;5(4)
57.
Jeong
W, Snell GI, Levvey BJ et al. Single-centre study of therapeutic drug
monitoring of posaconazole in lung transplant recipients: factors
affecting trough plasma concentrations. J Antimicrob Chemother .
2018;73(3):748-756
58.
U.S
FDA. Noxafil instruction. 2022;2022(2022/2/12)
59.
Khalil
HA, ElKhatib M, Belal TS, El-Yazbi AF, Hamdy DA. Hyperlipidemia Alters
the Pharmacokinetics of Posaconazole and Vincristine Upon
Co-Administration in Rats. Drugs R D . 2017;17(2):287-296
60.
Khalil
HA, Elnaggar MM, Belal TS, El-Yazbi AF, Hamdy DA. The effect of
hyperlipidemia on the pharmacokinetics, hepatic and pulmonary uptake of
posaconazole in rat. Eur J Pharm Sci . 2016;91:190-5
61.
Fevery
J. Bilirubin in clinical practice: a review. Liver Int .
2008;28(5):592-605
62.
Emiroglu
MY, Esen OB, Bulut M et al. GGT levels in type II diabetic patients with
acute coronary syndrome (does diabetes have any effect on GGT levels in
acute coronary syndrome?). Acta Diabetol . 2013;50(1):21-5
63.
Ermis
N, Yagmur J, Acikgoz N et al. Serum gamma-glutamyl transferase (GGT)
levels and inflammatory activity in patients with non-dipper
hypertension. Clin Exp Hypertens . 2012;34(5):311-5
64.
Caravaca-Fontán
F, Azevedo L, Bayo MÁ et al. High levels of both serum gamma-glutamyl
transferase and alkaline phosphatase are independent preictors of
mortality in patients with stage 4-5 chronic kidney disease.Nefrologia . 2017;37(3):267-275
65.
Sun D,
Liu H, Ouyang Y, Liu X, Xu Y. Serum Levels of Gamma-Glutamyltransferase
During Stable and Acute Exacerbations of Chronic Obstructive Pulmonary
Disease. Med Sci Monit . 2020;26:e927771
66.
Anderson
GD. Pharmacogenetics and enzyme induction/inhibition properties of
antiepileptic drugs. Neurology . 2004;63(10 Suppl 4):S3-8
67.
Rae
JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective,
pleiotropic inducer of drug metabolism genes in human hepatocytes:
studies with cDNA and oligonucleotide expression arrays. J
Pharmacol Exp Ther . 2001;299(3):849-57
68.
Sansone-Parsons
A, Krishna G, Calzetta A et al. Effect of a nutritional supplement on
posaconazole pharmacokinetics following oral administration to healthy
volunteers. Antimicrob Agents Chemother . 2006;50(5):1881-3
69.
Krishna
G, Ma L, Vickery D et al. Effect of varying amounts of a liquid
nutritional supplement on the pharmacokinetics of posaconazole in
healthy volunteers. Antimicrob Agents Chemother .
2009;53(11):4749-52
70.
Courtney
R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the
relative bioavailability of two oral formulations of posaconazole in
healthy adults. Br J Clin Pharmacol . 2004;57(2):218-22
71.
Lin
TY, Yang MH, Chang FY. A randomized, phase I, 3-way crossover study to
examine the effects of food on the pharmacokinetics of single doses of
400 mg posaconazole oral suspension in healthy male Taiwanese subjects.Ther Drug Monit . 2013;35(2):223-7
72. Li
H, Wei Y, Zhang S et al. Pharmacokinetics and Safety of Posaconazole
Administered by Intravenous Solution and Oral Tablet in Healthy Chinese
Subjects and Effect of Food on Tablet Bioavailability. Clin Drug
Investig . 2019;39(11):1109-1116
73.
Wei
XC, Zhao MF, Li X, Xiao X. Evaluating posaconazole dosing regimens of
the different formulations against Aspergillus spp. in adults: a
pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.Int J Antimicrob Agents . 2020;56(4):106112
74.
Wiederhold
NP. Pharmacokinetics and safety of posaconazole delayed-release tablets
for invasive fungal infections. Clin Pharmacol . 2016;8:1-8
75.
Sime
FB, Byrne CJ, Parker S et al. Population pharmacokinetics of total and
unbound concentrations of intravenous posaconazole in adult critically
ill patients. Crit Care . 2019;23(1):205
76.
Gastine
S, Hope W, Hempel G et al. Pharmacodynamics of Posaconazole in
Experimental Invasive Pulmonary Aspergillosis: Utility of Serum
Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.Antimicrob Agents Chemother . 2021;65(2)